rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 drugs reduce intracranial pressure and headache burden in idiopathic intracranial hypertension

RPEP-136772025Stefanou, Maria-Ioanna; Chatziralli, Irini; Lambadiari, Vaia; Mengel, Annerose; Foska, Aikaterini; Chondrogianni, Maria; Bakola, Eleni; Tsalouchidou, Panagiota-Eleni; Mitsikostas, Dimos D; Siasos, Gerasimos; Ziemann, Ulf; Tsivgoulis, Georgios
evidence
The takeaway

Systematic review and meta-analysis shows GLP-1 and GIP/GLP-1 receptor agonists significantly reduce intracranial pressure, headache burden, and BMI in idiopathic intracranial hypertension through weight-dependent and weight-independent mechanisms.

Dual mechanism in IIH

GLP-1 drugs reduce intracranial pressure through both weight loss AND direct CSF secretion reduction—potentially superior to current IIH treatments

What the researchers found

GLP-1/GIP agonists significantly reduced: intracranial pressure, headache burden (frequency + severity), BMI. Evidence of both weight-dependent and weight-independent mechanisms. CSF secretion reduction demonstrated.

Why it matters

IIH causes devastating vision loss and chronic headaches, with limited effective treatments. GLP-1 drugs could become a disease-modifying therapy addressing both the underlying obesity and the intracranial pressure directly.

How the study worked

Systematic review and meta-analysis of GLP-1 and GIP/GLP-1 RA studies in IIH.

What this study cannot tell us

Limited number of studies. Heterogeneous study designs. Small patient numbers. Long-term efficacy unknown.

How to read the evidence

Systematic review and meta-analysis of available evidence. Growing but still limited study base.

When this study was published

Published in 2025.

The bigger picture

IIH treatment is being transformed by GLP-1 drugs. The dual mechanism—weight loss plus direct CSF secretion reduction—makes them potentially more effective than any current therapy.

Questions still open

  • Could GLP-1 drugs replace acetazolamide as first-line IIH treatment?
  • Is the CSF secretion reduction mechanism direct or indirect?
  • Which GLP-1 drug is most effective for IIH?

Common questions

What is idiopathic intracranial hypertension?
IIH is a condition where pressure inside the skull is abnormally high without a tumor or other clear cause. It causes severe headaches and can lead to vision loss. It is strongly associated with obesity, particularly in young women.
How do GLP-1 drugs help IIH?
They help in two ways: (1) by causing significant weight loss, which reduces the obesity that drives IIH, and (2) by directly reducing the production of cerebrospinal fluid (the liquid surrounding the brain), which lowers intracranial pressure. This dual mechanism may make them more effective than current treatments.

Read the original research

Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.

European journal of neurology, 32(9), e70358

View on PubMed ↗Publisher’s paper ↗

Citation

Stefanou, Maria-Ioanna; Chatziralli, Irini; Lambadiari, Vaia; Mengel, Annerose; Foska, Aikaterini; Chondrogianni, Maria; Bakola, Eleni; Tsalouchidou, Panagiota-Eleni; Mitsikostas, Dimos D; Siasos, Gerasimos; Ziemann, Ulf; Tsivgoulis, Georgios. (2025). Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.. European journal of neurology, 32(9), e70358. https://doi.org/10.1111/ene.70358